EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis

Vallerie V McLaughlin, Marius M Hoeper iD, David B Badesch, H Ardeschir Ghofrani iD, J Simon R Gibbs, Mardi Gomberg-Maitland iD, Ioana R Preston, Rogerio Souza iD, Aaron B Waxman, Grzegorz Kopeć, Gisela Meyer, Karen M Olsson und 11 weitere

New England Journal of Medicine · 23.10.2025 · 393 (16) · 1599-1611

DOI: 10.1056/nejmoa2508170 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 23.10.2025. Verfasst von Vallerie V McLaughlin und 22 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan Medical School, Ann Arbor. Hauptthemen laut MEDLINE: Activins, Hypertension, Pulmonary, Pulmonary Arterial Hypertension, Recombinant Fusion Proteins. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ActivinsHypertension, PulmonaryPulmonary Arterial HypertensionRecombinant Fusion ProteinsAdultAgedFemaleHumansMaleMiddle AgedDisease ProgressionDouble-Blind MethodDrug Therapy, CombinationHospitalizationKaplan-Meier EstimateFollow-Up StudiesEpistaxisTelangiectasisExercise TestTreatment Outcome

Substanzen

ActivinsRecombinant Fusion Proteinssotatercept

Autor:innen und Institutionen

  • University of Michigan Medical School, Ann Arbor.
  • Hannover Medical School and the German Center for Lung Research, Hannover, Germany.
  • University of Colorado, Anschutz Medical Campus, Aurora.
  • Department of Internal Medicine, Justus-Liebig University Giessen, Universities of Giessen and Marburg Lung Center, Member of the German Center for Lung Research, Giessen, Germany.
  • National Heart and Lung Institute, Imperial College London, London.
  • George Washington University School of Medicine and Health Sciences, Washington, DC.

ORCID-Profile: Marius M Hoeper, H Ardeschir Ghofrani, Mardi Gomberg-Maitland, Rogerio Souza, Marc Humbert

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Zitieren

APA

McLaughlin, V. V., Hoeper, M. M., Badesch, D. B., Ghofrani, H. A., Gibbs, J. S. R., Gomberg-Maitland, M., Preston, I. R., Souza, R., Waxman, A. B., Kopeć, G., Meyer, G., Olsson, K. M., Fu, W., Shi, Y., Miller, B., Kim, S. S., Mackenzie, H. S., Brambatti, M., Patel, M. J., …, & HYPERION Trial Investigators (2025). Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. New England Journal of Medicine, 393(16), 1599-1611. https://doi.org/10.1056/nejmoa2508170

Vancouver

McLaughlin VV, Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, et al. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. New England Journal of Medicine. 2025;393(16):1599-1611. doi:10.1056/nejmoa2508170

BibTeX
@article{McLaughlin2025,
  author = {McLaughlin, Vallerie V and Hoeper, Marius M and Badesch, David B and Ghofrani, H Ardeschir and Gibbs, J Simon R and Gomberg-Maitland, Mardi and Preston, Ioana R and Souza, Rogerio and Waxman, Aaron B and Kopeć, Grzegorz and Meyer, Gisela and Olsson, Karen M and Fu, Wei and Shi, Yaru and Miller, Barry and Kim, Samuel S and Mackenzie, Harald S and Brambatti, Michela and Patel, Mahesh J and Koglin, Joerg and Cornell, Alexandra G and Humbert, Marc and HYPERION Trial Investigators, HYPERION Trial Investigators},
  title = {Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {16},
  pages = {1599--1611},
  doi = {10.1056/nejmoa2508170}
}
Kostenlos starten →